multiregion sequencing. The New England journal of Medicine. 2012;
366(10):883-92.
72. Gerlinger M, Horswell S, Larkin J, Rowan AJ, Salm MP, Varela I, et
al. Genomic architecture and evolution of clear cell renal cell carcinomas
defined by multiregion sequencing. Nat Genet. 2014;46(3):225-33.
73. TRACERx Renal: tracking renal cancer evolution through therapy.
Nature Reviews Urology. 2017;14(10):575-6.
74. Turajlic S, Xu H, Litchfield K, Rowan A, Horswell S, Chambers T, et
al. Deterministic Evolutionary Trajectories Influence Primary Tumor
Growth: TRACERx Renal. Cell. 2018;173(3):595-610 e11.
75. Turajlic S, Xu H, Litchfield K, Rowan A, Chambers T, Lopez JI, et al.
Tracking Cancer Evolution Reveals Constrained Routes to Metastases:
TRACERx Renal. Cell. 2018;173(3):581-94 e12.
76. Sierant MC, Choi J. Single-Cell Ssequencing in Cancer: Recent Applications
to Immunogenomics and Multi-omics Tools. Genomics Inform.
2018;16(4):e17-e.
77. Schmidt L, Duh F-M, Chen F, Kishida T, Glenn G, Choyke P, et al.
Germline and somatic mutations in the tyrosine kinase domain of the
MET proto-oncogene in papillary renal carcinomas. Nature Genetics.
1997;16(1):68.
78. Schmidt L, Junker K, Nakaigawa N, Kinjerski T, Weirich G, Miller
M, et al. Novel mutations of the MET proto-oncogene in papillary renal
carcinomas. Oncogene. 1999;18(14):2343.
79. Choueiri TK, Escudier B, Powles T, Tannir NM, Mainwaring PN, Rini
BI, et al. Cabozantinib versus everolimus in advanced renal cell carcinoma
(METEOR): final results from a randomised, open-label, phase 3
trial. The Lancet Oncology. 2016;17(7):917-27.
80. Martínez Chanzá N, Xie W, Asim Bilen M, Dzimitrowicz H, Burkart
J, Geynisman DM, et al. Cabozantinib in advanced non-clear-cell renal
cell carcinoma: a multicentre, retrospective, cohort study. The Lancet
Oncology. 2019;20(4):581-90.
81. Scheuermann TH, Tomchick DR, Machius M, Guo Y, Bruick RK,
Gardner KH. Artificial ligand binding within the HIF2 PAS-B domain
of the HIF2 transcription factor. Proceedings of the National Academy
of Sciences. 2009;106(2):450-5.
82. Scheuermann TH, Li Q, Ma HW, Key J, Zhang L, Chen R, et al. Allosteric
inhibition of hypoxia inducible factor-2 with small molecules.
Nat Chem Biol. 2013;9(4):271-6.
83. Wallace EM, Rizzi JP, Han G, Wehn PM, Cao Z, Du X, et al. A Small-
Molecule Antagonist of HIF2alpha Is Efficacious in Preclinical Models
of Renal Cell Carcinoma. Cancer Res. 2016;76(18):5491-500.
84. Cho H, Du X, Rizzi JP, Liberzon E, Chakraborty AA, Gao W, et al.
On-target efficacy of a HIF-2alpha antagonist in preclinical kidney cancer
models. Nature. 2016;539(7627):107-11.
85. Courtney KD, Ma Y, Diaz LA, Christie A, Xie Z, Woolford L, et al.
HIF-2 Complex Dissociation, Target Inhibition, and Acquired Resistance
with First-in-cClass HIF-2 Inhibitor in Patients. Clinical Cancer Research.
published online ahead of print November 19, 2019
86. Courtney KD, Infante JR, Lam ET, Figlin RA, Rini BI, Brugarolas J,
et al. Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-
Inducible Factor-2alpha Antagonist in Patients With Previously Treated
Advanced Clear Cell Renal Cell Carcinoma. J Clin Oncol. 2018;36(9):
867-74.
87. Jonasch E, Plimack ER, Bauer T, Merchan JR, Papadopoulos KP, Mc-
Dermott DF, et al. 911PDA first-in-human phase I/II trial of the oral
HIF-2a inhibitor PT2977 in patients with advanced RCC. Annals of Oncology.
2019;30(Supplement_5).
88. Kaelin WG, Jr. Synthetic lethality: a framework for the development
of wiser cancer therapeutics. Genome Med. 2009;1(10):99.
89. Turcotte S, Chan DA, Sutphin PD, Hay MP, Denny WA, Giaccia AJ.
A Molecule Targeting VHL-Deficient Renal Cell Carcinoma that Induces
Autophagy. Cancer Cell. 2008;14(1):90-102.
90. Chan DA, Sutphin PD, Nguyen P, Turcotte S, Lai EW, Banh A, et al.
Targeting GLUT1 and the Warburg Effect in Renal Cell Carcinoma by
Chemical Synthetic Lethality. Science Translational Medicine. 2011;3(94):
94ra70-94ra70.
91. Woldemichael GM, Turbyville TJ, Vasselli JR, Linehan WM, McMahon
JB. Lack of a functional VHL gene product sensitizes renal cell carcinoma
104 Kidney Cancer Journal
cells to the apoptotic effects of the protein synthesis inhibitor
verrucarin A. Neoplasia. 2012;14(8):771-7.
92.Woldemichael GM, Turbyville TJ, Linehan WM, McMahon JB.
Carminomycin I Is an Apoptosis Inducer That Targets the Golgi Complex
in Clear Cell Renal Carcinoma Cells. Cancer Research. 2011;
71(1):134-42.
93. Wolff NC, Pavía-Jiménez A, Tcheuyap VT, Alexander S, Vishwanath
M, Christie A, et al. High-throughput simultaneous screen and counterscreen
identifies homoharringtonine as synthetic lethal with von
Hippel-Lindau loss in renal cell carcinoma. Oncotarget. 2015;6(19):
16951-62.
94. Thompson JM, Nguyen QH, Singh M, Pavesic MW, Nesterenko I,
Nelson LJ, et al. Rho-associated kinase 1 inhibition is synthetically
lethal with von Hippel-Lindau deficiency in clear cell renal cell carcinoma.
Oncogene. 2017;36(8):1080-9.
95. Bommi-Reddy A, Almeciga I, Sawyer J, Geisen C, Li W, Harlow E, et
al. Kinase requirements in human cells: III. Altered kinase requirements
in VHL-/- cancer cells detected in a pilot synthetic lethal screen. Proc
Natl Acad Sci USA. 2008;105(43):16484-9.
96. Chakraborty AA, Nakamura E, Qi J, Creech A, Jaffe JD, Paulk J, et
al. HIF activation causes synthetic lethality between the VHL tumor
suppressor and the EZH1 histone methyltransferase. Science Translational
Medicine. 2017;9(398).
97. LaFave LM, Beguelin W, Koche R, Teater M, Spitzer B, Chramiec A,
et al. Loss of BAP1 function leads to EZH2-dependent transformation.
Nat Med. 2015;21(11):1344-9.
98. Dey A, Seshasayee D, Noubade R, French DM, Liu J, Chaurushiya
MS, et al. Loss of the Tumor Suppressor BAP1 Causes Myeloid Transformation.
Science. 2012;337(6101):1541-6.
99. Ho TH, Kapur P, Eckel-Passow JE, Christie A, Joseph RW, Serie DJ,
et al. Multicenter Validation of Enhancer of Zeste Homolog 2 Expression
as an Independent Prognostic Marker in Localized Clear Cell Renal
Cell Carcinoma. J Clin Oncol. 2017;35(32):3706-13.
100. Sun C, Zhao C, Li S, Wang J, Zhou Q, Sun J, et al. EZH2 Expression
is increased in BAP1-mutant renal clear cell carcinoma and is related
to poor prognosis. J Cancer. 2018;9(20):3787-96.
101. Adelaiye-Ogala R, Budka J, Damayanti NP, Arrington J, Ferris M,
Hsu CC, et al. EZH2 Modifies Sunitinib Resistance in Renal Cell Carcinoma
by Kinome Reprogramming. Cancer Res. 2017;77(23):6651-66.
102. O’Leary B, Finn RS, Turner NC. Treating cancer with selective
CDK4/6 inhibitors. Nature Reviews Clinical Oncology. 2016;13:417.
103. Logan JE, Mostofizadeh N, Desai AJ, E VONE, Conklin D,
Konkankit V, et al. PD-0332991, a potent and selective inhibitor of cyclin
dependent kinase 4/6, demonstrates inhibition of proliferation in
renal cell carcinoma at nanomolar concentrations and molecular markers
predict for sensitivity. Anticancer Res. 2013;33(8):2997-3004.
104. Small J, Washburn E, Millington K, Zhu J, Holder SL. The addition
of abemaciclib to sunitinib induces regression of renal cell carcinoma
xenograft tumors. Oncotarget. 2017;8(56):95116-34.
105. Nicholson HE, Tariq Z, Housden BE, Jennings RB, Stransky LA,
Perrimon N, et al. HIF-independent synthetic lethality between CDK4/6
inhibition and VHL loss across species. Sci Signal. 2019;12(601).
106. JSingh, A., et al. (2016). "Small Molecule Inhibitor of NRF2 Selectively
Intervenes Therapeutic Resistance in KEAP1-Deficient NSCLC Tumors."
ACS Chemical Biology 11(11): 3214-3225.
107. Telkoparan-Akillilar P, Suzen S, Saso L. Pharmacological Applications
of Nrf2 Inhibitors as Potential Antineoplastic Drugs. International
Journal of Molecular Sciences. 2019;20(8):2025.
108. Fabrizio FP, Costantini M, Copetti M, la Torre A, Sparaneo A,
Fontana A, et al. Keap1/Nrf2 pathway in kidney cancer: frequent
methylation of KEAP1 gene promoter in clear renal cell carcinoma. Oncotarget.
2017;8(7):11187-98.
109. Ji S, Xiong Y, Zhao X, Liu Y, Yu LQ. Effect of the Nrf2-ARE signaling
pathway on biological characteristics and sensitivity to sunitinib in renal cell
carcinoma. Oncol Lett. 2019;17(6):5175-86.
110. Jiang Z-Y, Lu M-C, You Q-D. Nuclear Factor Erythroid 2-Related
Factor 2 (Nrf2) Inhibition: An Emerging Strategy in Cancer Therapy.
Journal of Medicinal Chemistry. 2019;62(8):3840-56. KCJ